First Header Logo Second Header Logo

Connection

Waldemar Debinski to Humans

This is a "connection" page, showing publications Waldemar Debinski has written about Humans.
Connection Strength

0.910
  1. Sharma P, Debinski W. Receptor-Targeted Glial Brain Tumor Therapies. Int J Mol Sci. 2018 Oct 25; 19(11).
    View in: PubMed
    Score: 0.041
  2. Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W. Simultaneous targeting of Eph receptors in glioblastoma. Oncotarget. 2016 Sep 13; 7(37):59860-59876.
    View in: PubMed
    Score: 0.035
  3. Ferluga S, Debinski W. Ephs and Ephrins in malignant gliomas. Growth Factors. 2014 Dec; 32(6):190-201.
    View in: PubMed
    Score: 0.031
  4. Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W. Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors. J Neurooncol. 2014 Feb; 116(3):447-54.
    View in: PubMed
    Score: 0.029
  5. Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM. New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors. PLoS One. 2013; 8(10):e77719.
    View in: PubMed
    Score: 0.029
  6. Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W. Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase. J Biol Chem. 2013 Jun 21; 288(25):18448-57.
    View in: PubMed
    Score: 0.028
  7. Pandya H, Debinski W. Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy. BioDrugs. 2012 Aug 01; 26(4):235-44.
    View in: PubMed
    Score: 0.026
  8. Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W. EphrinA1 is released in three forms from cancer cells by matrix metalloproteases. Mol Cell Biol. 2012 Aug; 32(16):3253-64.
    View in: PubMed
    Score: 0.026
  9. Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W. Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor. J Biol Chem. 2012 Apr 20; 287(17):14012-22.
    View in: PubMed
    Score: 0.026
  10. Beauchamp A, Debinski W. Ephs and ephrins in cancer: ephrin-A1 signalling. Semin Cell Dev Biol. 2012 Feb; 23(1):109-15.
    View in: PubMed
    Score: 0.025
  11. Pandya H, Gibo DM, Garg S, Kridel S, Debinski W. An interleukin 13 receptor a 2-specific peptide homes to human Glioblastoma multiforme xenografts. Neuro Oncol. 2012 Jan; 14(1):6-18.
    View in: PubMed
    Score: 0.025
  12. Debinski W, Gibo DM. Fos-related antigen 1 (Fra-1) pairing with and transactivation of JunB in GBM cells. . 2011 Jan 15; 11(2):254-62.
    View in: PubMed
    Score: 0.024
  13. Debinski W, Tatter SB. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation. Curr Opin Mol Ther. 2010 Dec; 12(6):647-53.
    View in: PubMed
    Score: 0.024
  14. Debinski W, Tatter SB. Convection-enhanced delivery for the treatment of brain tumors. Expert Rev Neurother. 2009 Oct; 9(10):1519-27.
    View in: PubMed
    Score: 0.022
  15. Liu TF, Cai J, Gibo DM, Debinski W. Reoxygenation of hypoxic glioblastoma multiforme cells potentiates the killing effect of an interleukin-13-based cytotoxin. Clin Cancer Res. 2009 Jan 01; 15(1):160-8.
    View in: PubMed
    Score: 0.021
  16. Chen J, Zhuang G, Frieden L, Debinski W. Eph receptors and Ephrins in cancer: common themes and controversies. Cancer Res. 2008 Dec 15; 68(24):10031-3.
    View in: PubMed
    Score: 0.021
  17. Wykosky J, Debinski W. The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res. 2008 Dec; 6(12):1795-806.
    View in: PubMed
    Score: 0.021
  18. Mintz A, Gibo DM, Madhankumar AB, Cladel NM, Christensen ND, Debinski W. Protein- and DNA-based active immunotherapy targeting interleukin-13 receptor alpha2. Cancer Biother Radiopharm. 2008 Oct; 23(5):581-9.
    View in: PubMed
    Score: 0.020
  19. Debinski W. Drug cocktails for effective treatment of glioblastoma multiforme. Expert Rev Neurother. 2008 Apr; 8(4):515-7.
    View in: PubMed
    Score: 0.020
  20. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor alpha 2, EphA2, and Fos-related antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res. 2008 Jan 01; 14(1):199-208.
    View in: PubMed
    Score: 0.019
  21. Wykosky J, Gibo DM, Debinski W. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor expressing tumor cells. . 2007 Dec; 6(12 Pt 1):3208-18.
    View in: PubMed
    Score: 0.019
  22. Debinski W. Naturally occurring, unmodified bacterial toxin for the treatment of glioblastoma multiforme? . 2006 Nov; 5(11):1569-70.
    View in: PubMed
    Score: 0.018
  23. Wykosky J, Gibo DM, Stanton C, Debinski W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol Cancer Res. 2005 Oct; 3(10):541-51.
    View in: PubMed
    Score: 0.016
  24. Debinski W. Personalized, multivalent, and more affordable: the globalization of vaccines. Clin Cancer Res. 2005 Aug 15; 11(16):5663-4.
    View in: PubMed
    Score: 0.016
  25. Debinski W, Gibo DM. Fos-related antigen 1 modulates malignant features of glioma cells. Mol Cancer Res. 2005 Apr; 3(4):237-49.
    View in: PubMed
    Score: 0.016
  26. Madhankumar AB, Mintz A, Debinski W. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2. Neoplasia. 2004 Jan-Feb; 6(1):15-22.
    View in: PubMed
    Score: 0.015
  27. Mintz A, Gibo DM, Madhankumar AB, Debinski W. Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma. J Neurooncol. 2003 Aug-Sep; 64(1-2):117-23.
    View in: PubMed
    Score: 0.014
  28. Debinski W, Gibo D, Mintz A. Epigenetics in high-grade astrocytomas: opportunities for prevention and detection of brain tumors. Ann N Y Acad Sci. 2003 Mar; 983:232-42.
    View in: PubMed
    Score: 0.014
  29. Mintz A, Gibo DM, Slagle-Webb B, Christensen ND, Debinski W. IL-13Ralpha2 is a glioma-restricted receptor for interleukin-13. Neoplasia. 2002 Sep-Oct; 4(5):388-99.
    View in: PubMed
    Score: 0.013
  30. Madhankumar AB, Mintz A, Debinski W. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine. J Biol Chem. 2002 Nov 08; 277(45):43194-205.
    View in: PubMed
    Score: 0.013
  31. Debinski W. Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest. 2002; 20(5-6):801-9.
    View in: PubMed
    Score: 0.013
  32. Mao C, Li F, Zhao Y, Debinski W, Ming X. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Theranostics. 2018; 8(22):6274-6290.
    View in: PubMed
    Score: 0.010
  33. Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns? Neuroradiology. 2018 Oct; 60(10):1043-1051.
    View in: PubMed
    Score: 0.010
  34. Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE. Hypoxia-inducible factor 2a: a novel target in gliomas. Future Med Chem. 2018 09 01; 10(18):2227-2236.
    View in: PubMed
    Score: 0.010
  35. Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X. P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release. 2018 09 28; 286:289-300.
    View in: PubMed
    Score: 0.010
  36. McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD. Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide. Am J Clin Oncol. 2018 08; 41(8):813-819.
    View in: PubMed
    Score: 0.010
  37. Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB, Watabe K. Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis. Cancer Res. 2018 08 01; 78(15):4316-4330.
    View in: PubMed
    Score: 0.010
  38. Su W, Hong L, Xu X, Huang S, Herpai D, Li L, Xu Y, Truong L, Hu WY, Wu X, Xiao C, Zhang W, Han J, Debinski W, Xiang R, Sun P. miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways. Oncogene. 2018 10; 37(42):5618-5632.
    View in: PubMed
    Score: 0.010
  39. Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW. Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44. Cancer Res. 2018 05 15; 78(10):2589-2600.
    View in: PubMed
    Score: 0.010
  40. Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B. Use of non-ionizing electromagnetic fields for the treatment of cancer. Front Biosci (Landmark Ed). 2018 Jan 01; 23:284-297.
    View in: PubMed
    Score: 0.010
  41. Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS. Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant. Biophys J. 2017 Jul 25; 113(2):472-480.
    View in: PubMed
    Score: 0.009
  42. Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27; 8(26):42997-43007.
    View in: PubMed
    Score: 0.009
  43. Randolph DM, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD. Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma. Clin Neurol Neurosurg. 2016 Dec; 151:73-78.
    View in: PubMed
    Score: 0.009
  44. Qian X, Tan H, Zhang J, Liu K, Yang T, Wang M, Debinskie W, Zhao W, Chan MD, Zhou X. Identification of biomarkers for pseudo and true progression of GBM based on radiogenomics study. Oncotarget. 2016 Aug 23; 7(34):55377-55394.
    View in: PubMed
    Score: 0.009
  45. Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS. The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence. Future Oncol. 2016 Sep; 12(17):2009-20.
    View in: PubMed
    Score: 0.009
  46. Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X. Pseudo progression identification of glioblastoma with dictionary learning. Comput Biol Med. 2016 06 01; 73:94-101.
    View in: PubMed
    Score: 0.009
  47. Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J. Treatment of brain metastases of lung cancer in the era of precision medicine. Front Biosci (Elite Ed). 2016 Jan 01; 8:219-32.
    View in: PubMed
    Score: 0.008
  48. Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW. The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis. Oncotarget. 2015 Sep 08; 6(26):22653-65.
    View in: PubMed
    Score: 0.008
  49. Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD. Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases. Oncotarget. 2015 Aug 07; 6(22):18945-55.
    View in: PubMed
    Score: 0.008
  50. Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design. J Neurooncol. 2015 Sep; 124(3):447-53.
    View in: PubMed
    Score: 0.008
  51. Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW. Mechanisms regulating glioma invasion. Cancer Lett. 2015 Jun 28; 362(1):1-7.
    View in: PubMed
    Score: 0.008
  52. Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD. Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma. J Neurooncol. 2014 Sep; 119(2):429-35.
    View in: PubMed
    Score: 0.008
  53. Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol. 2014 Apr; 37(2):177-81.
    View in: PubMed
    Score: 0.007
  54. Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G. Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer. Neoplasia. 2013 Oct; 15(10):1172-83.
    View in: PubMed
    Score: 0.007
  55. Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A. A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Ra2 tumor-restricted biomarker. Neuro Oncol. 2012 Oct; 14(10):1239-53.
    View in: PubMed
    Score: 0.007
  56. Candolfi M, Xiong W, Yagiz K, Liu C, Muhammad AK, Puntel M, Foulad D, Zadmehr A, Ahlzadeh GE, Kroeger KM, Tesarfreund M, Lee S, Debinski W, Sareen D, Svendsen CN, Rodriguez R, Lowenstein PR, Castro MG. Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics. Proc Natl Acad Sci U S A. 2010 Nov 16; 107(46):20021-6.
    View in: PubMed
    Score: 0.006
  57. Schwartzbaum JA, Ahlbom A, Lönn S, Malmer B, Wigertz A, Auvinen A, Brookes AJ, Collatz Christensen H, Henriksson R, Johansen C, Salminen T, Schoemaker MJ, Swerdlow AJ, Debinski W, Feychting M. An international case-control study of interleukin-4Ralpha, interleukin-13, and cyclooxygenase-2 polymorphisms and glioblastoma risk. Cancer Epidemiol Biomarkers Prev. 2007 Nov; 16(11):2448-54.
    View in: PubMed
    Score: 0.005
  58. Schwartzbaum J, Ahlbom A, Malmer B, Lönn S, Brookes AJ, Doss H, Debinski W, Henriksson R, Feychting M. Polymorphisms associated with asthma are inversely related to glioblastoma multiforme. Cancer Res. 2005 Jul 15; 65(14):6459-65.
    View in: PubMed
    Score: 0.004
  59. Zhou G, Ye GJ, Debinski W, Roizman B. Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci U S A. 2002 Nov 12; 99(23):15124-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.